Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 497

1.

Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, Antvelink CM, Penson DF, Thompson IM.

J Urol. 2007 Apr;177(4):1395-400; quiz 1591.

PMID:
17382740
2.

Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.

Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL.

J Urol. 2009 Feb;181(2):710-6. doi: 10.1016/j.juro.2008.10.025. Epub 2008 Dec 16.

PMID:
19091352
3.

Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.

Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G.

J Urol. 2006 Sep;176(3):1051-6.

PMID:
16890690
4.

Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.

Parsons JK, Sarma AV, McVary K, Wei JT.

J Urol. 2009 Dec;182(6 Suppl):S27-31. doi: 10.1016/j.juro.2009.07.086. Review.

PMID:
19846130
5.

Obesity and benign prostatic hyperplasia.

Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, Willett WC.

Am J Epidemiol. 1994 Dec 1;140(11):989-1002.

PMID:
7527182
6.

Physical activity and benign prostatic hyperplasia.

Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer MJ, Willett WC, Giovannucci E.

Arch Intern Med. 1998 Nov 23;158(21):2349-56.

PMID:
9827786
7.

Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study.

Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E.

J Urol. 2000 Feb;163(2):490-5.

PMID:
10647663
8.

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.

J Urol. 2008 Oct;180(4):1228-34. doi: 10.1016/j.juro.2008.06.079. Epub 2008 Aug 22.

PMID:
18722631
9.

Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia.

Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW.

J Urol. 2002 Aug;168(2):599-604.

PMID:
12131317
10.
11.

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F; CombAT Study Group.

J Urol. 2008 Feb;179(2):616-21; discussion 621. Epub 2007 Dec 21. Erratum in: J Urol. 2008 Sep;180(3):1191.

PMID:
18082216
12.

Lower urinary tract symptoms are associated with depressive symptoms in white, black and Hispanic men in the United States.

Laumann EO, Kang JH, Glasser DB, Rosen RC, Carson CC.

J Urol. 2008 Jul;180(1):233-40. doi: 10.1016/j.juro.2008.03.055. Epub 2008 May 21.

PMID:
18499181
13.

Prevention of benign prostatic hyperplasia disease.

Marks LS, Roehrborn CG, Andriole GL.

J Urol. 2006 Oct;176(4 Pt 1):1299-306. Review.

PMID:
16952616
14.

Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.

Fukuta F, Masumori N, Mori M, Tsukamoto T.

Int J Urol. 2013 Jan;20(1):100-6. doi: 10.1111/j.1442-2042.2012.03215.x. Epub 2012 Oct 29.

15.

Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study.

Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E.

J Urol. 2010 Sep;184(3):1040-4. doi: 10.1016/j.juro.2010.05.033.

PMID:
20643424
16.

Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia.

Irani J, Lefebvre O, Murat F, Dahmani L, Doré B.

BJU Int. 2003 Apr;91(6):482-4.

17.

Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS.

J Urol. 2007 Apr;177(4):1401-7.

PMID:
17382741
18.

The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.

Paranhos M, Antunes A, Andrade E, Freire G, Srougi M.

BJU Int. 2009 Oct;104(8):1130-3. doi: 10.1111/j.1464-410X.2009.08562.x. Epub 2009 May 5.

19.

Incidence rates and risk factors for acute urinary retention: the health professionals followup study.

Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I.

J Urol. 1999 Aug;162(2):376-82.

PMID:
10411042
20.

Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study.

Seitter WR, Barrett-Connor E.

Am J Epidemiol. 1992 Mar 1;135(5):500-3.

PMID:
1373933

Supplemental Content

Support Center